evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

958 questions · 991 findings · 123 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 177 · 17.9%GRADE not reported 25 · 2.5%Very low 230 · 23.2%Low 321 · 32.4%Moderate 185 · 18.7%High 53 · 5.3%

Etanercept vs intravenous immunoglobulin (IVIG)

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Cyclosporin vs intravenous immunoglobulin (IVIG)

Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

It is very uncertain whether cyclosporin changes disease‐specific mortality (time to compared with intravenous immunoglobulin (IVIG) (very low certainty).

1 finding from 1 review

Cyclosporin vs intravenous immunoglobulin (IVIG)

Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Cyclosporin vs intravenous immunoglobulin (IVIG)

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Intra‐arterial delivery vs intravenous delivery

Vessel patency ‐ radiological success ‐ complete (to end of treatment) · patients with < 30 days' limb ischaemiaa

Intra‐arterial delivery may leads to higher vessel patency ‐ radiological success ‐ complete (to end of treatment) compared with intravenous delivery (low certainty).

1 finding from 1 review

Chloral hydrate oral (75 mg/kg) vs pentobarbital intravenous (5 mg/kg)

Proportion of children who had sedation failure after 1 dose of sedative agent · children undergoing neurodiagnostic procedures

Chloral hydrate oral (75 mg/kg) may leads to higher proportion of children who had sedation failure after 1 dose of… compared with pentobarbital intravenous (5 mg/kg) (low certainty).

1 finding from 1 review

Chloral hydrate oral (75 mg/kg) vs pentobarbital intravenous (5 mg/kg)

Proportion of children who had sedation failure after 2 doses of sedative agent (same or different) · children undergoing neurodiagnostic procedures

It is very uncertain whether chloral hydrate oral (75 mg/kg) changes proportion of children who had sedation failure after 2 doses of… compared with pentobarbital intravenous (5 mg/kg) (very low certainty).

1 finding from 1 review

Chloral hydrate oral (75 mg/kg) vs pentobarbital intravenous (5 mg/kg)

Non‐interpretable neuroimaging finding · children undergoing neurodiagnostic procedures

It is very uncertain whether chloral hydrate oral (75 mg/kg) changes non‐interpretable neuroimaging finding compared with pentobarbital intravenous (5 mg/kg) (very low certainty).

1 finding from 1 review

Chloral hydrate oral (75 mg/kg) vs pentobarbital intravenous (5 mg/kg)

Number of children with clinical adverse event: oxygen desaturation · children undergoing neurodiagnostic procedures

It is very uncertain whether chloral hydrate oral (75 mg/kg) changes number of children with clinical adverse event: oxygen desaturation compared with pentobarbital intravenous (5 mg/kg) (very low certainty).

1 finding from 1 review

Chloral hydrate oral (75 mg/kg) vs pentobarbital intravenous (5 mg/kg)

Proportion of children who required a further dose of either the same sedative agent or the addition of a different sedative agent · children undergoing neurodiagnostic procedures

The review found no eligible studies for this question.

1 finding from 1 review